OncoMatch/Triple-Negative Breast Cancer (TNBC)/PIK3CA

Triple-Negative Breast Cancer (TNBC)PIK3CA Clinical Trials

PIK3CA activating mutations occur in approximately 10–15% of TNBC and activate the PI3K/AKT/mTOR axis, creating a therapeutic opportunity distinct from HR+ breast cancer. AKT inhibitors (capivasertib, ipatasertib) are being evaluated in PIK3CA/AKT1/PTEN-altered TNBC in combination with chemotherapy. Trials investigate pan-PI3K and isoform-selective inhibitors, PARP inhibitor combinations exploiting HRD co-occurrence, and biomarker-stratified immunotherapy combinations.